Evidence receipt
FLOW: what the trial found
A plain-language summary of one study: who took part, what they got, what it was compared with, what happened in each group, its limits and who paid for it. One trial. Results are group averages, not a prediction for any one person.
Study: FLOW[1]
Does semaglutide 1 mg protect the kidneys in people with type 2 diabetes and chronic kidney disease?
- Who was in it
- 3,533 adults with type 2 diabetes and chronic kidney disease
- What they got
- Semaglutide 1 mg injection once a week
- Compared with
- Placebo
- How long
- Median 3.4 years (stopped early because of benefit)
- What happened
- Major kidney disease events: 331 people on semaglutide vs 410 on placebo.
- Relative effect
- Hazard ratio 0.76 (95% CI 0.66–0.88) for major kidney events
- Limits
- Stopped early, which can overstate an effect
- Only people with type 2 diabetes
- Funded by
- Novo Nordisk
Summary by Joshua Nichvolodoff, from the published paper — not written by the study's authors. Clinical review: not yet reviewed by a clinician.
Sources
- Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). New England Journal of Medicine, July 11, 2024. https://pubmed.ncbi.nlm.nih.gov/38785209/ · DOI 10.1056/NEJMoa2403347 · PMID 38785209. Accessed November 2, 2026. Back to the text
Discussed in: Ozempic, explained
General information, not medical advice.